Docetaxel

Phase III ARTEMIS‑011 showed median PFS 5.5 vs 1.4 months (HR 0.33); safety showed high rates of grade ≥3 TRAEs with Ris‑Rez versus chemotherapy.

Phase 1b study shows pasritamig and docetaxel combo is safe and effective in prostate cancer, with high PSA response rates, supporting Phase 3 trials.